Undifferentiated Connective Tissue Disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc)

Autoimmunity Reviews

Volumn 14, Issue 3, 2015, Pages 210-213

  Valentini, Gabriele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Nailfold videocapillaroscopy; Scleroderma; Scleroderma spectrum antibodies; Undifferentiated Connective Tissue Disease

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER;

ANTIBODY DETECTION; CAPILLAROSCOPY; CONNECTIVE TISSUE DISEASE; DISEASE SEVERITY; HIGH RISK PATIENT; HUMAN; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; SCLERODERMA; SYSTEMIC SCLEROSIS; UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE; ANIMAL; COMPLICATION; IMMUNOLOGY; RISK FACTOR;

ANIMALS; AUTOANTIBODIES; BIOLOGICAL MARKERS; CONNECTIVE TISSUE DISEASES; HUMANS; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84920938733     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.11.002     Document Type: Review

References (51)

1. Deane K.D., El-Gabalawy H. Pathogenesis and prevention of rheumatic disease. Nat Rev Rheumatol 2014, 10:212-228.
2. Tramposch H.D., Smith C.D., Senecal J.L., Rothfield N. A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum 1984, 27:121-124.
3. Prete M., Fatone M.C., Favoino E., Perosa F. Raynaud's phenomenon: from molecular pathogenesis to therapy. Autoimmun Rev 2014, 13:655-667.
4. Koenig M., Joyal F., Fritzler M.J., Roussin A., Abrahamowicz M., Boire G., et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008, 58:3902-3912.
5. Matucci Cerinic M., Allanore Y., Czirjak L., Tyndall A., Muller-Ladner U., Denton C., et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop prevention or rescue strategy. Ann Rheum Dis 2009, 68:1377-1380.
6. Avouac J., Fransen J., Walker U.A., Riccieri V., Smith V., Muller C., et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR Scleroderma Trials and Research group. Ann Rheum Dis 2011, 70:476-481.
7. Valentini G., Cuomo G., Abignano G., Petrillo A., Vettori S., Capasso A., et al. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 2011, 50:317-323.
8. Valentini G., Vettori S., Cuomo G., Iudici M., D'Abrosca V., Capocotta D., et al. Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement. Arthritis Res Ther 2012, 14:R188.
9. Matucci-Cerinic M., Bellando-Randone S., Lepri G., Bruni C., Guiducci S. Very early versus early disease: the evolving definition of the 'many faces' of systemic sclerosis. Ann Rheum Dis 2013, 72:319-321.
10. Valentini G., Marcoccia A., Cuomo G., Vettori S., Iudici M., Bondanini F., et al. Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. Arthritis Res Ther 2013, 15:R63.
11. Minier T., Guiducci S., Bellando-Randone S., Bruni C., Lepri G., Czirják L., et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2014, 73:2087-2093.
12. Lepri G., Guiducci S., Bellando Randone S., Giani I., Bruni C., Blagojevic J., et al. Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. Ann Rheum Dis Jan 28 2014, [Epub ahead of print]. 10.1136/annrheumdis-2013-203889.
13. Valentini G., Marcoccia A., Cuomo G., Vettori S., Iudici M., Bondanini F., et al. Early systemic sclerosis: analysis of the disease course in patients with marker autoantibodies or capillaroscopic positivity or both. Arthritis Care Res 2014, 66:1520-1527.
14. Vettori S., Cuomo G., Iudici M., D'Abrosca V., Giacco V., Barra G., et al. Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol 2014, 34:663-668.
15. Valentini G., Marcoccia A., Cuomo G., Iudici M., Vettori S. The concept of early systemic sclerosis following 2013 ACR\EULAR Criteria for the Classification of Systemic Sclerosis. Curr Rheumatol Rev 2014, 10:38-44.
16. Vigone B., Santaniello A., Marchini M., Montanelli G., Caronni M., Severino A., et al. Role of class II human leukocyte antigens in the progression from early to definite systemic sclerosis. Rheumatology September 16 2014, [Epub ahead of print; pii: keu381].
17. LeRoy E.C., Medsger T.A. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28:1573-7616.
18. Rossi D., Russo A., Manna E., Binello G., Baldovino S., Sciascia S., et al. The role of nail-videocapillaroscopy in early diagnosis of scleroderma. Autoimmun Rev 2013, 12:821-825.
19. Villalta D., Imbastaro T., Di Giovanni S., Lauriti C., Gabini M., Turi M.C., et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 2012, 12:114-120.
20. Mehra S., Walker J., Patterson K., Fritzler M.J. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013, 12:340-354.
21. Subcommittee Criteria of the AmericanRheumatism Association Diagnostic and TherapeuticCriteria Committee Preliminary criteria for classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
22. van den Hoogen F., Khanna D., Fransen J., Johnson S.R., Baron M., Tyndall A., et al. Classification Criteria for Systemic Sclerosis: an ACR-EULAR collaborative initiative. Arthritis Rheum 2013, 65:2737-2747.
23. Matucci-Cerinic M., Kahaleh B., Wigley F.M. Evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013, 65:1953-1962.
24. Poormoghin H., Lucas M., Fertig N., Medsger T.A. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000, 43:444-451.
25. Pope J. Personal communication 2014.
26. Mosca M., Tani C., Talarico R., Bombardieri S. Undifferentiated Connective Tissue Diseases (UCTD): simplified systemic autoimmune diseases. Autoimmun Rev 2011, 10:256-258.
27. Hinchcliff M., Fischer A., Schiopu E., Steen V.D. PHAROS Investigators. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011, 38:2172-2179.
28. Hsu V.M., Chung L., Hummers L.K., Wigley F., Simms R., Bolster M., et al. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum 2014, 44:55-62.
29. Campbell P.M., LeRoy E.C. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975, 4:351-368.
30. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003.
31. Gilbane A.J., Denton C.P., Holmes A.M. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther 2013, 15:215.
32. Hortstman M., Mertens F., Stam H. Transfer factor for carbon monoxide. European respiratory Society Monograph 2005, 10:127-147. R. Gosselink, R. Stam (Eds.).
33. Fahey P.J., Utell M.J., Condemi J.J., Green R., Hyde R.W. Raynaud's phenomenon of the lung. Am J Med 1984, 76:263-269.
34. Sjogren R.W. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994, 37:1265-1282. Review.
35. Labovitz A.J., Pearson A.C. Evaluation of left ventricular diastolic dysfunction: clinical relevance and recent Doppler echocardiographic insights. Am Heart J 1987, 114:836-851.
36. Belch J.J., Land D., Park R.H., McKillop J.H., Mackenzie J.F. Decreased esophageal blood flow in patients with Raynaud's phenomenon. Br J Rheumatol 1988, 27:426-430.
37. Tschöpe C., Westermann D., Steendijk P., Kasner M., Rudwaleit M., Schwimmbeck P.L., et al. Coronary vasospasm-induced acute diastolic dysfunction in a patient with Raynaud's phenomenon. Clin Res Cardiol 2006, 95:344-348.
38. Mosca M., Virdis A., Tani C., Ghiadoni L., Versari D., Duranti E., et al. Vascular reactivity in patients with Undifferentiated Connective Tissue Diseases. Atherosclerosis 2009, 203:185-191.
39. Saban J., Rodriguez Garcia J.L., Pais J.R., Mellado N., Munoz E. Raynaud's phenomenon with digital necrosis as the first manifestations of undifferentiated connective tissue syndrome. Dermatologica 1991, 182:121-123.
40. Emery P., Salmon M. Early rheumatoid arthritis: time to aim for remission?. Ann Rheum Dis 1995, 54:944-947.
41. Medsger T.A. Classification, prognosis. Systemic sclerosis 2004, 17-28. Lippincott William&Wilkins, Philadelphia. 2nd ed. P.J. Clements, D.E. Furst (Eds.).
42. Wuttge D.M., Lood C., Tufvesson E., Scheja A., Truedsson L., Bengtsson A.A., et al. Increased serum type I interferon activity in early systemic sclerosis is associated with antibodies against Sjögren's syndrome antigens and nuclear ribonucleoprotein antigens. Scand J Rheumatol 2013, 42:235-240.
43. Young E.A., Steen V.D., Medsger T.A. Systemic sclerosis without Raynaud's phenomenon. Arthritis Rheum 1986, 29(Suppl. 4):S51 A. Abstract.
44. Meier F.M., Frommer K.W., Dinser R., Walker U.A., Czirjak L., Denton C.P., et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012, 71:1355-1360.
45. Castelino F.V., Varga J. Current status of systemic sclerosis biomarkers: application for diagnosis, management and drug development. Expert Rev Clin Immunol 2013, 9:1077-1090.
46. Shanmugam V.K., Steen V.D. Renal disease in scleroderma: an update on evaluation, risk stratification and management. Curr Opin Rheumatol 2012, 24:669-676.
47. Chaisson N.F., Hassoun P.M. Systemic sclerosis-associated pulmonary arterial hypertension. Chest 2013, 144:1346-1563.
48. Tingley T., Shu J., Smuczek J., Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken) 2013, 65:1460-1471.
49. Vij R., Strek M.E. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013, 143:814-824.
50. van Laar J.M., Sullivan K. Stem cell transplantation in systemic sclerosis. Curr Opin Rheumatol 2013, 25:719-725.
51. Distler A., Lang V., Del Vecchio T., Huang J., Zhang Y., Beyer C., et al. Combined inhibition of morphogen pathways demonstrates additive antifibrotic effect and improved tolerability. Ann Rheum Dis 2014, 73:1264-1268.